Real-World Evidence of the Effectiveness and Safety of Ustekinumab for the Treatment of Crohn’s Disease: Systematic Review and Meta-Analysis of Observational Studies
Published 2022 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Real-World Evidence of the Effectiveness and Safety of Ustekinumab for the Treatment of Crohn’s Disease: Systematic Review and Meta-Analysis of Observational Studies
Authors
Keywords
-
Journal
Journal of Clinical Medicine
Volume 11, Issue 14, Pages 4202
Publisher
MDPI AG
Online
2022-07-20
DOI
10.3390/jcm11144202
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Long-Term Real-World Effectiveness and Safety of Ustekinumab in Crohn’s Disease Patients: The SUSTAIN Study
- (2022) María Chaparro et al. INFLAMMATORY BOWEL DISEASES
- Effectiveness of ustekinumab in patients with refractory Crohn’s disease: a multicentre real-life study in Italy
- (2022) Maria Lia Scribano et al. Therapeutic Advances in Gastroenterology
- Long-term effectiveness and safety of ustekinumab in bio-naïve and bio-experienced anti-tumor necrosis factor patients with Crohn’s disease: a real-world multicenter Brazilian study
- (2022) Rogério Serafim Parra et al. BMC GASTROENTEROLOGY
- Five-year Efficacy and Safety of Ustekinumab Treatment in Crohn’s Disease: the IM-UNITI trial
- (2021) William J. Sandborn et al. Clinical Gastroenterology and Hepatology
- Re-induction With Intravenous Ustekinumab in Patients With Crohn’s Disease and a Loss of Response to This Therapy
- (2021) Fernando Bermejo et al. INFLAMMATORY BOWEL DISEASES
- Effectiveness and Safety of Ustekinumab in Inflammatory Bowel Disease: A Systematic Review and Meta-Analysis
- (2021) Sailish Honap et al. DIGESTIVE DISEASES AND SCIENCES
- Prospective observational study on Stelara (ustekinumab) assessing effectiveness in Crohn’s disease (PROSE): a 16-week follow-up
- (2021) Anders Forss et al. SCANDINAVIAN JOURNAL OF GASTROENTEROLOGY
- A nationwide real-world study on dynamic ustekinumab dosing and concomitant medication use among Crohn’s disease patients in Finland
- (2021) Taina Sipponen et al. SCANDINAVIAN JOURNAL OF GASTROENTEROLOGY
- Clinical efficacy, drug sustainability and serum drug levels in Crohn's disease patients treated with ustekinumab – A prospective, multicenter cohort from Hungary
- (2021) Lorant Gonczi et al. DIGESTIVE AND LIVER DISEASE
- Real-World Effectiveness and Safety of Ustekinumab in Elderly Crohn’s Disease Patients
- (2021) Rajat Garg et al. DIGESTIVE DISEASES AND SCIENCES
- Safety and effectiveness of ustekinumab in Crohn's disease: Interim results of post‐marketing surveillance in Japan
- (2021) Seiji Yokoyama et al. JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY
- Experience Using Ustekinumab in Pediatric Patients with Medically Refractory Crohn's Disease
- (2021) Francis S. Kim et al. JOURNAL OF PEDIATRIC GASTROENTEROLOGY AND NUTRITION
- Incidence comparison of adverse events in patients with inflammatory bowel disease receiving different biologic agents: retrospective long-term evaluation
- (2021) Brigida Barberio et al. Intestinal Research
- A propensity score‐matched, real‐world comparison of ustekinumab vs vedolizumab as a second‐line treatment for Crohn’s disease. The Cross Pennine study II
- (2021) Marco Vincenzo Lenti et al. ALIMENTARY PHARMACOLOGY & THERAPEUTICS
- Real-world use of mycophenolate mofetil in inflammatory bowel disease: Results from the ENEIDA registry
- (2021) A. Hernández-Camba et al. DIGESTIVE AND LIVER DISEASE
- Primary Failure to an Anti-TNF Agent in Inflammatory Bowel Disease: Switch (to a Second Anti-TNF Agent) or Swap (for Another Mechanism of Action)?
- (2021) Javier P. Gisbert et al. Journal of Clinical Medicine
- P737 Ustekinumab induction effectiveness in Crohn’s disease in a real-life cohort
- (2020) E Sánchez Rodríguez et al. Journal of Crohns & Colitis
- P697 Efficacy and safety of ustekinumab in Crohn’s disease: A real-world study from Australia
- (2020) P Kakkadasam Ramaswamy et al. Journal of Crohns & Colitis
- P507 Ustekinumab: Medium-term outcomes from a UK multicentre real-world cohort
- (2020) R Gadhok et al. Journal of Crohns & Colitis
- P484 Effectiveness and safety of ustekinumab in patients with Crohn’s disease: a real-world experience
- (2020) D Mohammad et al. Journal of Crohns & Colitis
- P665 Which second-line biologic after anti-TNF failure during Crohn’s disease: Ustekinumab or vedolizumab, a multicentre retrospective study
- (2020) C Rayer et al. Journal of Crohns & Colitis
- P381 Use of ustekinumab in Crohn’s disease: Singapore largest single-centre experience
- (2020) H H Shim et al. Journal of Crohns & Colitis
- P577 Ustekinumab in actual clinical practice: our centre experience
- (2020) J M LOPEZ TOBARUELA et al. Journal of Crohns & Colitis
- P344 Effectiveness of ustekinumab in refractory Crohn’s disease: A real-life experience in a tertiary referral centre
- (2020) M Truyens et al. Journal of Crohns & Colitis
- P545 Deep remission assessed by endoscopy, magnetic resonance or intestinal ultrasound, in refractory Crohn’s disease patients in clinical remission with ustekinumab: a real-life single-centre experience
- (2020) M I Calvo Moya et al. Journal of Crohns & Colitis
- Safety and effectiveness of ustekinumab for induction of remission in patients with Crohn’s disease: A multicenter Israeli study
- (2020) Ariella Bar-Gil Shitrit et al. United European Gastroenterology Journal
- The effectiveness of either ustekinumab or vedolizumab in 239 patients with Crohn's disease refractory to anti-tumour necrosis factor
- (2020) Hadrien Alric et al. ALIMENTARY PHARMACOLOGY & THERAPEUTICS
- Effectiveness of ustekinumab dose escalation in Crohn’s disease patients with insufficient response to standard-dose subcutaneous maintenance therapy
- (2020) Uri Kopylov et al. ALIMENTARY PHARMACOLOGY & THERAPEUTICS
- Ustekinumab Does Not Increase Risk of Adverse Events: A Meta-Analysis of Randomized Controlled Trials
- (2020) Vineet S. Rolston et al. DIGESTIVE DISEASES AND SCIENCES
- Real-world long-term effectiveness of ustekinumab in Crohn's disease: results from the ENEIDA registry
- (2020) Marisa Iborra et al. ALIMENTARY PHARMACOLOGY & THERAPEUTICS
- Comparative effectiveness of ustekinumab or vedolizumab after one year in 130 patients with anti-TNF-refractory Crohn’s disease
- (2020) Tristan Townsend et al. ALIMENTARY PHARMACOLOGY & THERAPEUTICS
- Objectively assessed disease activity and drug persistence during ustekinumab treatment in a nationwide real-world Crohn’s disease cohort
- (2020) Clas-Göran af Björkesten et al. EUROPEAN JOURNAL OF GASTROENTEROLOGY & HEPATOLOGY
- Ustekinumab in bio-naïve and bio-failure Crohn's disease patients: Results from a « real-life » monocentric cohort.
- (2020) L. Monin et al. DIGESTIVE AND LIVER DISEASE
- Real‐world effectiveness and safety of ustekinumab for the treatment of Crohn’s disease: The Scottish ustekinumab Cohort
- (2020) N Plevris et al. JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY
- Ustekinumab Exposure-outcome Analysis in Crohn’s Disease Only in Part Explains Limited Endoscopic Remission Rates
- (2019) Bram Verstockt et al. Journal of Crohns & Colitis
- Long-term clinical effectiveness of ustekinumab in patients with Crohn’s disease who failed biological therapies: a national cohort study
- (2019) Claire Liefferinckx et al. Journal of Crohns & Colitis
- Colorectal cancer and adenoma screening using urinary volatile organic compound (VOC) detection: early results from a single-centre bowel screening population (UK BCSP)
- (2019) E. Mozdiak et al. Techniques in Coloproctology
- Effectiveness and safety of Ustekinumab for Crohn's disease; systematic review and pooled analysis of real-world evidence
- (2019) Tal Engel et al. DIGESTIVE AND LIVER DISEASE
- IM-UNITI: Three-year Efficacy, Safety, and Immunogenicity of Ustekinumab Treatment of Crohn’s Disease
- (2019) Stephen B Hanauer et al. Journal of Crohns & Colitis
- Ustekinumab for Crohn’s Disease: Results of the ICC Registry, a Nationwide Prospective Observational Cohort Study
- (2019) Vince B C Biemans et al. Journal of Crohns & Colitis
- Ustekinumab: “Real-world” outcomes and potential predictors of nonresponse in treatment-refractory Crohn’s disease
- (2019) Peter Hoffmann et al. WORLD JOURNAL OF GASTROENTEROLOGY
- ECCO Guidelines on Therapeutics in Crohn’s Disease: Surgical Treatment
- (2019) Michel Adamina et al. Journal of Crohns & Colitis
- Predictors of Primary Response to Biologic Treatment [Anti-TNF, Vedolizumab, and Ustekinumab] in Patients With Inflammatory Bowel Disease: From Basic Science to Clinical Practice
- (2019) Javier P Gisbert et al. Journal of Crohns & Colitis
- ECCO Guidelines on Therapeutics in Crohn's Disease: Medical Treatment
- (2019) Joana Torres et al. Journal of Crohns & Colitis
- Effectiveness and safety of Ustekinumab for the treatment of Crohn’s disease in real-life experiences: a meta-analysis of observational studies
- (2019) Fabio Salvatore Macaluso et al. EXPERT OPINION ON BIOLOGICAL THERAPY
- Eficacia y seguridad de ustekinumab en la práctica clínica real. Estudio multicéntrico retrospectivo. Cohorte ARAINF
- (2019) Diego Casas Deza et al. Gastroenterologia y Hepatologia
- Short and Long-Term Effectiveness of Ustekinumab in Patients with Crohn’s Disease: Real-World Data from a German IBD Cohort
- (2019) Alica Kubesch et al. Journal of Clinical Medicine
- Long-term efficacy and safety of ustekinumab in 122 refractory Crohn's disease patients: a multicentre experience
- (2018) P. Wils et al. ALIMENTARY PHARMACOLOGY & THERAPEUTICS
- Illuminating the Black Box: The Real Risk of Serious Infection With Inflammatory Bowel Disease Therapies
- (2018) Amanda M. Lynn et al. GASTROENTEROLOGY
- Efficacy of Ustekinumab for Inducing Endoscopic Healing in Patients With Crohn’s Disease
- (2018) Paul Rutgeerts et al. GASTROENTEROLOGY
- Ustekinumab en el tratamiento de la enfermedad de Crohn
- (2017) Javier P. Gisbert et al. Gastroenterologia y Hepatologia
- Long-term Maintenance of Clinical, Endoscopic, and Radiographic Response to Ustekinumab in Moderate-to-Severe Crohnʼs Disease
- (2017) Christopher Ma et al. INFLAMMATORY BOWEL DISEASES
- Ustekinumab use in Crohn’s disease: a Canadian tertiary care centre experience
- (2017) Astrid-Jane Greenup et al. SCANDINAVIAN JOURNAL OF GASTROENTEROLOGY
- Patients with Refractory Crohnʼs Disease Successfully Treated with Ustekinumab
- (2016) Kimberly A. Harris et al. INFLAMMATORY BOWEL DISEASES
- Ustekinumab for the Treatment of Refractory Crohnʼs Disease
- (2016) Sam Khorrami et al. INFLAMMATORY BOWEL DISEASES
- Ustekinumab as Induction and Maintenance Therapy for Crohn’s Disease
- (2016) Brian G. Feagan et al. NEW ENGLAND JOURNAL OF MEDICINE
- Inflammatory Bowel Disease and the Risk of Autoimmune Diseases
- (2015) J. Claire Wilson et al. Journal of Crohns & Colitis
- Subcutaneous ustekinumab for the treatment of anti-TNF resistant Crohn's disease—The McGill experience
- (2014) U. Kopylov et al. Journal of Crohns & Colitis
- Thiopurine methyl-transferase activity and azathioprine metabolite concentrations do not predict clinical outcome in thiopurine-treated inflammatory bowel disease patients
- (2011) Y. González-Lama et al. ALIMENTARY PHARMACOLOGY & THERAPEUTICS
- Therapeutic Drug Monitoring of Biologics for Inflammatory Bowel Disease
- (2011) Jean-Frédéric Colombel et al. INFLAMMATORY BOWEL DISEASES
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreBecome a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get Started